Cytotoxicity of etoposide in cancer cell lines In Vitro after BCL-2 AND C-RAF gene silencing with antisense oligonucleotides

Acta Poloniae Pharmaceutica - Drug Research

Volumn 70, Issue 1, 2013, Pages 87-97

  Sypniewski, Daniel ^a   Bednarek, Ilona ^a   Gałka, Sabina ^a   Loch, Tomasz ^a   Błaszczyk, Daria ^a   Sołtysik, Dagna ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Antisense oligonucleotides; Apoptosis; BCL 2; C RAF; Cancer; Etoposide; PTGS; Real time RT PCR

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ETOPOSIDE; HISTONE H3; MESSENGER RNA; PROTEIN BCL 2; RAF PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTO ONCOGENE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL SHAPE; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HELA CELLS; HISTONES; HUMANS; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-RAF; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; TRANSFECTION;

EID: 84872948245     PISSN: 00016837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Niault T.S., Baccarini M.: Carcinogenesis 31, 1165 (2010).
2. Madhunapantula S.V., Robertson G.P.: Cancer Res. 68, 5 (2008).
3. Haferlach C., Dicker F., Kohlmann A. et al.: Leukemia 24, 1065 (2010).
4. Sun H., He H., Zhang S., Liu T., Ren K., He Q., Shao R.: Cancer Gene Ther. 16, 693 (2009).
5. Sasi N., Hwang M., Jaboin J., Csiki I., Lu B.: Mol. Cancer Ther. 8, 1421 (2009).
6. Brunelle J.K., Letai A.: J. Cell Sci. 122, 437 (2009).
7. Tredan O., Galmarini C.M., Patel K., Tannock I.F.: J. Natl. Cancer Inst. 99, 1441 (2007).
8. Bednarek I., Sypniewski D., Solarz J., Machnik G., Gałka S., Loch T.: Wiad. Lek. 61, 4 (2008).
9. Orchel J., Słowiński J., Mazurek U., Wilczok T.: Biochim. Biophys. Acta 1689, 42 (2004).
10. Wu H., Lima W.F., Zhang H., Fan A., Sun H., Crooke S.T.: J. Biol. Chem. 279, 17181 (2004).
11. Hofmann M.H., Heinrich J., Radziwil G., Moelling K.: Mol. Cancer Ther. 7, 1635 (2009).
12. Benvenuti S., Sartore-Bianchi A., Di Nicolantonio F. et al.: Cancer Res. 67, 2643 (2007).
13. Davis J.M., Navolanic P.M., Weinstein-Oppenheimer C.R. et al.: Clin. Cancer Res. 9, 1161 (2003).
14. Guinness M.E., Kenney J.L., Reiss M., Lacy J.: Cancer Res. 60, 5354 (2000).
15. Bednarek I., Czajka M., Wilczok T.: Folia Histochem. Cytobiol. 40, 133 (2002).
16. Zangemeister-Wittke U., Leech S.H., Olie R.A. et al.: Clin. Cancer Res. 6, 2547 (2000).
17. Nahta R., Esteva F.J.: Semin. Oncol. 30, 143 (2003).
18. Liu Q., Gazitt Y.: Blood 101, 4105 (2003).
19. Hu Y.P., Bebb G., Tan S. et al.: Clin. Cancer Res. 10, 7662 (2004).
20. Rudin C.M., Kozloff M., Hoffman P.C. et al.: J. Clin. Oncol. 22, 1110 (2004).
21. Yip K.W., Mocanu J.D., Billie Au P.Y. et al.: Clin. Cancer Res. 11, 8131 (2005).
22. Zupi G., Scarsella M., Semple S.C., Mottolese M., Natali P.G., Leonetti C.: Clin. Cancer Res. 11, 1990 (2005).
23. Klasa R.J., Bally M.B., Ng R., Goldie J.H., Gascoyne R.D., Wong F.M.: Clin. Cancer Res. 6, 2492 (2000).
24. Yamanaka K., Rocchi P., Miyake H., Fazli L., Vessella B., Zangemeister-Wittke U., Gleave M.E.: Mol. Cancer Ther. 4, 1689 (2005).
25. Tortora G., Caputo R., Damiano V. et al.: Clin. Cancer Res. 9, 866 (2003).
26. Lang S.A., Schachtschneider P., Moser C. et al.: Mol. Cancer Ther. 7, 3509 (2008).